Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
Economy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Last updated: April 23, 2025 6:12 pm
Share
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
SHARE

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that has been in the spotlight recently as one of the cheap NASDAQ stocks to buy according to hedge funds. With a forward P/E ratio of 13.24 and 74 hedge fund holders, Gilead is making waves in the industry.

In a recent interview on CNBC, Dan Ives, Head of Global Tech Research at Wedbush Securities, discussed the current state of the tech sector, highlighting the potential for major volatility ahead. The uncertainty in the tech industry has been exacerbated by escalating tariffs on China, reaching as high as 125%. This has forced companies to rethink their supply chains and has resulted in a noticeable pause in tech spending.

Despite the challenges, Ives has not downgraded tech stocks, emphasizing the potential for clear winners to emerge from the current turmoil. He predicts that Street estimates are likely to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.

Gilead Sciences has seen success in its HIV franchise, with sales reaching $19.6 billion in 2024. Key products like Biktarvy and Descovy have contributed to this growth, solidifying Gilead’s position in the market. While the company expects some temporary challenges in 2025 due to Medicare Part D reform, the underlying HIV business remains strong.

In a recent investor letter, ClearBridge Value Strategy praised Gilead’s performance, citing strong fourth-quarter earnings growth and positive reception to its new treatments. Overall, Gilead ranks 9th on the list of cheap NASDAQ stocks to buy according to hedge funds.

See also  PSQ Holdings doubles, becoming latest stock to rip higher on news of Donald Trump Jr.'s involvement

While Gilead shows promise, there are other opportunities in the market, particularly in AI stocks. These stocks have the potential to deliver high returns in a shorter time frame. If you’re looking for an AI stock with significant growth potential, consider exploring the cheapest AI stock highlighted in our report.

In conclusion, Gilead Sciences is positioned as a strong contender in the biopharmaceutical industry, with a solid track record and promising future prospects. However, investors should also consider exploring opportunities in AI stocks for potentially higher returns. Stay informed and make informed investment decisions based on the latest market trends and opportunities.

TAGGED:BuyCheapfundsGILDGileadhedgeNasdaqSciencesStock
Share This Article
Twitter Email Copy Link Print
Previous Article Can climate science attribute economic damage to major polluters? Can climate science attribute economic damage to major polluters?
Next Article How Legal Aid’s pro-crime push puts all of us in danger How Legal Aid’s pro-crime push puts all of us in danger
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Climate change could separate vanilla plants and their pollinators

Vanilla plants could have a future that’s not so sweet, according to new research that…

July 3, 2025

North Korea confirms it sent troops to Russia to support its war against Ukraine : NPR

Russian President Vladimir Putin, left, and North Korea's leader Kim Jong Un pose for a…

April 27, 2025

Remembering history in Trump’s America

Unlock the White House Watch newsletter for free Your guide to what Trump’s second term…

May 1, 2025

USMNT winners and losers with Mauricio Pochettino: Christian Pulisic up, Tyler Adams in trouble

The United States men's national team is on the brink of a major change with…

September 10, 2024

UN Says Trump Escalator Problem Likely Caused by Safety Trigger

This article was originally published  by The Epoch Times: UN Claims Trump Escalator Mishap Likely…

September 26, 2025

You Might Also Like

Elon Musk and former Twitter execs agree to settle 8 million lawsuit
Economy

Elon Musk and former Twitter execs agree to settle $128 million lawsuit

October 10, 2025
Should You Buy Novartis Stock Before October 28?
Economy

Should You Buy Novartis Stock Before October 28?

October 10, 2025
I’m a Financial Advisor: People Always Regret Doing These 5 Things With Their Roth IRA
Economy

I’m a Financial Advisor: People Always Regret Doing These 5 Things With Their Roth IRA

October 10, 2025
This Analyst Just Hiked Their UnitedHealth Stock Price Target by 50%. Should You Buy UNH Now?
Economy

This Analyst Just Hiked Their UnitedHealth Stock Price Target by 50%. Should You Buy UNH Now?

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?